Ethan Thompson

Bristol-Myers Squibb (United States) — United States

Medicine · Health Sciences

22h-index3.1kcitations125works1.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Research Studies(28), Neuroendocrine Tumor Research Advances(27), Multiple Myeloma Research and Treatments(24), Tuberculosis Research and Epidemiology(22), CAR-T cell therapy research(22)

Publications125 total

Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study
Leukemia·2026Open Access
Population-specific pangenome unveils a third FAD2 gene and solves the peanut mid-oleic fatty acid mystery
Nature Communications·2025Open Access
Impact of lenalidomide pre-apheresis on markers of T cell fitness and pharmacodynamic biomarkers in newly diagnosed multiple myeloma patients with suboptimal response to autologous stem cell transplantation
Blood·2025
Lisocabtagene maraleucel (liso-cel) demonstrates superior efficacy across inflammatory risk subgroups in second-line (2L) large B-cell lymphoma (LBCL): A retrospective analysis of the TRANSFORM study
Blood·2025Open Access
Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)
Blood·2025Open Access
Idecabtagene Vicleucel (ide-cel) and Endogenous Immune Profiles Linked to Progression-Free Survival in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Clinical Lymphoma Myeloma & Leukemia·2025
Distinct patient, tumour and chimeric antigen receptor T‐cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma
British Journal of Haematology·2025· 1 citedOpen Access
Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab
Therapeutic Advances in Hematology·2025Open Access
Assessment of normal plasma cell biomarkers after arlocabtagene autoleucel (arlo-cel) treatment in patients with ≥3L relapsed refractory multiple myeloma (MM).
Journal of Clinical Oncology·2025· 1 cited
High-resolution genetic and physical mapping reveals a peanut spotted wilt disease resistance locus, PSWDR-1, to Tomato spotted wilt virus (TSWV), within a recombination cold-spot on chromosome A01
BMC Genomics·2025· 4 citedOpen Access
Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (Pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (Tx) from the Phase 3, Randomized Transform Study
Transplantation and Cellular Therapy·2025
Genetic and genomic characterization of a multiparent advanced generation intercross (MAGIC) population of peanut ( <i>Arachis hypogaea</i> L.)
Crop Science·2024· 1 citedOpen Access
Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study
Blood·2024· 1 citedOpen Access
Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
Blood·2024
Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis
Blood·2024· 1 cited
Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
Blood·2024· 4 citedOpen Access
Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Blood·2024· 4 citedOpen Access
P-030 Low Infection Rates in Patients (pts) With Relapsed/Refractory Myeloma (RRMM) Treated With Alnuctamab (ALNUC) in a Setting of Infection Reduction Strategies (IRS) and Less Frequent Dosing
Clinical Lymphoma Myeloma & Leukemia·2024
P-045 Idecabtagene Vicleucel (ide-cel) in Patients (pts) With Clinical High-Risk Early Relapse Multiple Myeloma (MM) Without Front-Line (1L) Autologous Stem Cell Transplantation (ASCT): KarMMA-2 Cohort 2B
Clinical Lymphoma Myeloma & Leukemia·2024· 3 cited
P-069 Idecabtagene Vicleucel (ide-cel) in Patients (pts) with Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): the 5-year Follow-Up Analysis from KarMMa
Clinical Lymphoma Myeloma & Leukemia·2024· 2 cited
page 1 of 7Next →

Frequent Co-authors

Daniel E. Zak(20), Thomas J. Scriba(17), Gerhard Walzl(15), Adam Penn‐Nicholson(12), Sara Suliman(12), Steven G. Smith(12), Stefan H. E. Kaufmann(11), Mark Hatherill(10), Gerard Tromp(10), Jayne S. Sutherland(9), Michelle Fisher(9), Tom H. M. Ottenhoff(8), Willem A. Hanekom(8), Fergal J. Duffy(8), Hazel M. Dockrell(7), W. Henry Boom(7), André G. Loxton(7), Mzwandile Erasmus(6), Bonnie Thiel(6), Harriet Mayanja‐Kizza(6)